Auriga Laboratories, Inc., a specialty pharmaceutical company, engages in the development, commercialization, and licensing of pharmaceutical products in the areas of respiratory, dermatology, and anti-infective therapeutic categories. The companys product line includes Extendryl for the treatment of cough, cold, and allergy symptoms; Aquoral, a prescription product for the treatment of xerostomia or dry mouth; Levall used in the treatment and relief from cough, congestion, and rhinitis associated with respiratory infections, such as the common cold, influenza, bronchitis, and sinusitis; and Coraz Lotion for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, such as seborrheic dermatitis. Its products also include Zytopic Cream for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, such as atopic dermatitis; Zinx for relief of symptoms associated with common cold and allergies; Xyralid, which is used to reduce swelling and inflammation; and Akurza for the removal of excessive keratin in hyperkeratotic skin disorders. The company markets its products to primary care physicians, pediatricians, dermatologists, urologists, psychiatrists, and rheumatologists. It has a co-promotion agreement with Middlebrook Pharmaceuticals, Inc.; license agreement with Outlook Pharmaceuticals, Inc. and Ellevan LLC; and manufacturing and supply agreement with Mikart, Inc. The company was founded in 2005 and is headquartered in Camarillo, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for ARGA